← All trials
NCT00333164
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2006
- Primary completion
- Mar 1, 2012
- Completion date
- Mar 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Translational Research Informatics Center, Kobe, Hyogo, JapanLead sponsor
- Kobe UniversityOverall official - principal investigator
- Tokyo Women's Medical UniversityOverall official - principal investigator
- Foundation for Biomedical Research and InnovationCollaborator
- Tohoku UniversityCollaborator
- Kyushu UniversityCollaborator
- Kobe UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Tokyo Women's Medical UniversityCollaborator
- Saiseikai Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.